Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · IEX Real-Time Price · USD
10.38
-0.27 (-2.54%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 17.14, with a low estimate of 13 and a high estimate of 22. The average target predicts an increase of 65.13% from the current stock price of 10.38.
Analyst Consensus: Buy
* Price targets were last updated on May 14, 2024.
Analyst Ratings
The average analyst rating for FOLD stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 5 | 5 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Hold → Strong Buy Upgrades $13 | Hold → Strong Buy | Upgrades | $13 | +25.24% | May 14, 2024 |
| UBS | UBS | Strong Buy Maintains $20 → $19 | Strong Buy | Maintains | $20 → $19 | +83.04% | May 10, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $19 | Buy | Maintains | $20 → $19 | +83.04% | May 10, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +25.24% | May 10, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 10, 2024 |
Financial Forecast
Revenue This Year
520.60M
from 399.36M
Increased by 30.36%
Revenue Next Year
654.80M
from 520.60M
Increased by 25.78%
EPS This Year
-0.22
from -0.51
EPS Next Year
0.23
from -0.22
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 539.3M | 723.7M | 1.0B | 1.2B | 1.4B |
| Avg | 520.6M | 654.8M | 858.2M | 1.1B | 1.3B |
| Low | 497.3M | 589.1M | 671.6M | 935.9M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 35.0% | 39.0% | 55.9% | 38.4% | 33.1% |
| Avg | 30.4% | 25.8% | 31.1% | 25.8% | 20.3% |
| Low | 24.5% | 13.2% | 2.6% | 9.1% | 2.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.01 | 0.56 | 1.05 | 1.98 | 2.77 |
| Avg | -0.22 | 0.23 | 0.73 | 1.60 | 2.26 |
| Low | -0.34 | 0.11 | 0.35 | 1.22 | 1.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 351.5% | 170.2% | 73.7% |
| Avg | - | - | 215.8% | 117.4% | 41.5% |
| Low | - | - | 51.7% | 65.5% | 9.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.